Antiplatelet Therapy for Patients with Diabetes: More Is Better
In patients with ACS, the net clinical benefit of prasugrel, compared with clopidogrel, was greater for those who had diabetes than for those who didn’t.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)